MENU
+Compare
NCNA
Stock ticker: NASDAQ
AS OF
Aug 8 closing price
Price
$0.03
Change
-$0.00 (-0.00%)
Capitalization
12.29M

NCNA NuCana plc Forecast, Technical & Fundamental Analysis

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology... Show more

Industry: #Biotechnology
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NCNA with price predictions
Aug 08, 2025

NCNA in -20.30% downward trend, falling for three consecutive days on August 08, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NCNA declined for three days, in of 372 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NCNA as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for NCNA entered a downward trend on August 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NCNA advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

NCNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NCNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NCNA's P/B Ratio (434.783) is very high in comparison to the industry average of (18.702). P/E Ratio (0.000) is within average values for comparable stocks, (54.306). NCNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.011). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (287.256).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of novel anti-cancer medicines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3 Lochside Way
Phone
+44 1313571111
Employees
28
Web
https://www.nucana.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LOOP1.630.06
+3.82%
Loop Industries
ERIE357.324.72
+1.34%
Erie Indemnity Company
EYPT10.07N/A
N/A
EyePoint Pharmaceuticals
OSRH0.60-0.02
-2.44%
OSR Holdings Inc.

NCNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with RNAC. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-1.83%
RNAC - NCNA
93%
Closely correlated
-0.09%
AGEN - NCNA
93%
Closely correlated
N/A
TAOX - NCNA
92%
Closely correlated
+3.53%
ALLR - NCNA
86%
Closely correlated
-1.66%
NRXP - NCNA
85%
Closely correlated
N/A
More

Groups containing NCNA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-1.83%
NCNA
(6 stocks)
36%
Loosely correlated
-2.27%